<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00369070</url>
  </required_header>
  <id_info>
    <org_study_id>20060136</org_study_id>
    <nct_id>NCT00369070</nct_id>
  </id_info>
  <brief_title>A Phase 2 Trial of AMG 706 or Bevacizumab in Combination With Chemo for Advanced NSCLC</brief_title>
  <official_title>A Phase 2, Multicenter, Open Label, Randomized Trial of AMG 706 or Bevacizumab in Combination With Paclitaxel and Carboplatin for Advanced Non-squamous Non-small Cell Lung Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Amgen</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Amgen</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to estimate the difference in objective response rates between
      each paclitaxel/carboplatin plus AMG 706 arm (Arm A and B) and paclitaxel/carboplatin plus
      bevacizumab arm (Arm C) in subjects with advanced non-squamous NSCLC.
    </textblock>
  </brief_summary>
  <overall_status>Terminated</overall_status>
  <start_date type="Actual">January 31, 2007</start_date>
  <completion_date type="Actual">August 3, 2011</completion_date>
  <primary_completion_date type="Actual">April 23, 2008</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Objective tumor response rate</measure>
    <time_frame>Response assessments will be obtained every 6 +/- 1 week until subjects develop disease progression.</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Duration of response</measure>
    <time_frame>Time from first objective tumor response to disease progression or death, if the death was due to disease progression.</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression free survival</measure>
    <time_frame>Number of days from randomization tot he date of radiological evidence of disease progression or death.</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival</measure>
    <time_frame>Time from randomization to death.</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics of AMG 706 when administered with paclitaxel and carboplatin in Arms A and B</measure>
    <time_frame>From randomization until disease progression or death.</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety and tolerability in the 3 arms</measure>
    <time_frame>From randomization until disease progression or death.</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">186</enrollment>
  <condition>Advanced Non-squamous NSCLC</condition>
  <arm_group>
    <arm_group_label>A</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>AMG 706 125 mg once daily (QD) and paclitaxel and carboplatin chemotherapy regimen (paclitaxel 200 mg/m2 and carboplatin at AUC of 6 mg/mL x min) on day 1 of each 3 week cycle for a maximum of 6 cycles.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>B</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>AMG 706 75 mg twice daily every 12 ± approximately 1 hour for 5 days followed by a 2 day treatment free period every 7 days and paclitaxel and carboplatin chemotherapy regimen (paclitaxel 200 mg/m2 and carboplatin at AUC of 6 mg/mL x min) on day 1 of each 3 week cycle for a maximum of 6 cycles.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>C</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Bevacizumab 15 mg/kg bevacizumab, delivered via intravenous (IV) infusion once every 3 weeks and paclitaxel and carboplatin chemotherapy regimen (paclitaxel 200 mg/m2 and carboplatin at AUC of 6 mg/mL x min) on day 1 of each 3 week cycle for a maximum of 6 cycles.</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Bevacizumab</intervention_name>
    <description>15 mg/kg bevacizumab, delivered via intravenous (IV) infusion once every 3 weeks</description>
    <arm_group_label>C</arm_group_label>
    <other_name>Avastin</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>AMG 706</intervention_name>
    <description>subjects in Arms A and B will take AMG 706 orally in one of two dosing regimens over each 21-day cycle: •Arm A: 125 mg once daily (QD) •Arm B: 75 mg twice daily every 12 ± approximately 1 hour for 5 days followed by a 2 day treatment free period every 7 days</description>
    <arm_group_label>A</arm_group_label>
    <arm_group_label>B</arm_group_label>
    <other_name>Motesanib diphosphate</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Paclitaxel</intervention_name>
    <description>All subjects will receive a paclitaxel chemotherapy regimen (paclitaxel 200 mg/m2) on day 1 of each 3-week cycle for a maximum of 6 cycles.</description>
    <arm_group_label>A</arm_group_label>
    <arm_group_label>B</arm_group_label>
    <arm_group_label>C</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Carboplatin</intervention_name>
    <description>All subjects will receive carboplatin chemotherapy regimen (carboplatin at AUC of 6 mg/mL x min) on day 1 of each 3-week cycle for a maximum of 6 cycles.</description>
    <arm_group_label>A</arm_group_label>
    <arm_group_label>B</arm_group_label>
    <arm_group_label>C</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Men or women 18 years or older with histologically or cytologically confirmed advanced
             non-squamous NSCLC (unresectable stage IIIB with pericardial or pleural effusion or
             stage IV/recurrent)

          -  Measureable disease per RECIST criteria modified

          -  ECOG performance status of 0 or 1

          -  Ability to take oral medications

          -  Competent to give written informed consent

        Exclusion Criteria:

          -  Current or prior history of CNS metastases

          -  Any prior chemotherapy for advanced NSCLC

          -  History of pulmonary hemorrhage or gross hemoptysis within 6 months prior to
             randomization

          -  Prior targeted therapies

          -  Known history of allergy or hypersensitivity to paclitaxel or carboplatin

          -  History of arterial or venous thrombosis within 52 weeks prior to randomization

          -  History of bleeding diathesis or non-pulmonary bleeding within 14 days prior to
             randomization

          -  Peripheral neuropathy &gt; grade 1 per CTCAE Version 3.0

          -  Myocardial infarction, cerebrovascular accident, grade 2 or greater peripheral
             vascular disease, transient ischemic attack, congestive heart failure, percutaneous
             transluminal coronary angioplasty/stent, ongoing arrythmias requiring medication or
             unstable angina within 52 weeks prior to randomization

          -  Any kind of disorder that compromises the ability of the subject to comply with the
             study procedures

          -  Uncontrolled hypertension as defined by resting blood pressure &gt; 150/90 mm Hg.
             Anti-hypertensive medications are allowed if hypertension is stably controlled at the
             time of randomization.

          -  Participation in therapeutic clinical trials or currently receiving other
             investigational treatment(s) within 30 days prior to randomization

          -  Pregnant or breast feeding women

          -  Known to be HIV, hepatitis B surface antigen, or hepatitis C positive
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>MD</last_name>
    <role>Study Director</role>
    <affiliation>Amgen</affiliation>
  </overall_official>
  <removed_countries>
    <country>Hong Kong</country>
    <country>India</country>
    <country>United States</country>
  </removed_countries>
  <link>
    <url>http://www.amgentrials.com</url>
    <description>AmgenTrials clinical trials website</description>
  </link>
  <reference>
    <citation>Blumenschein GR Jr, Kabbinavar F, Menon H, Mok TS, Stephenson J, Beck JT, Lakshmaiah K, Reckamp K, Hei YJ, Kracht K, Sun YN, Sikorski R, Schwartzberg L; Motesanib NSCLC Phase II Study Investigators. A phase II, multicenter, open-label randomized study of motesanib or bevacizumab in combination with paclitaxel and carboplatin for advanced nonsquamous non-small-cell lung cancer. Ann Oncol. 2011 Sep;22(9):2057-67. doi: 10.1093/annonc/mdq731. Epub 2011 Feb 14.</citation>
    <PMID>21321086</PMID>
  </reference>
  <reference>
    <citation>Claret L, Lu JF, Bruno R, Hsu CP, Hei YJ, Sun YN. Simulations using a drug-disease modeling framework and phase II data predict phase III survival outcome in first-line non-small-cell lung cancer. Clin Pharmacol Ther. 2012 Nov;92(5):631-4. doi: 10.1038/clpt.2012.78. Epub 2012 Aug 22.</citation>
    <PMID>22910440</PMID>
  </reference>
  <verification_date>January 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 24, 2006</study_first_submitted>
  <study_first_submitted_qc>August 24, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 29, 2006</study_first_posted>
  <disposition_first_submitted>December 14, 2015</disposition_first_submitted>
  <disposition_first_submitted_qc>December 14, 2015</disposition_first_submitted_qc>
  <disposition_first_posted type="Estimate">January 14, 2016</disposition_first_posted>
  <last_update_submitted>January 2, 2018</last_update_submitted>
  <last_update_submitted_qc>January 2, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">January 4, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>AMG 706</keyword>
  <keyword>Bevacizumab</keyword>
  <keyword>Paclitaxel and Carboplatin</keyword>
  <keyword>Randomized</keyword>
  <keyword>Non-Small Cell Lung Cancer</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Paclitaxel</mesh_term>
    <mesh_term>Albumin-Bound Paclitaxel</mesh_term>
    <mesh_term>Bevacizumab</mesh_term>
    <mesh_term>Carboplatin</mesh_term>
    <mesh_term>Niacinamide</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted, but a results disposition has been submitted           -->
</clinical_study>

